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Abstract
Introduction: Collagen peptides have been reported to possess various biological activities for various cell types.
The purposes of this study were, first, to examine the therapeutic effects of collagen tripeptide (Ctp) in rabbit
osteoarthritis and, second, to explore a synergetic effect with hyaluronan (HA).
Methods: Osteoarthritis was induced by anterior cruciate ligament transection of the right knee in 72 Japanese
white rabbits and they were divided into four groups (control, Ctp, HA and Ctp/HA). Each material was injected
weekly into the knee, and knee joint samples were collected 5, 10 and 15 weeks after surgery. Macroscopic and
histomorphological analyses of cartilage were conducted. Expression of type II collagen and matrix
metalloproteinase-13 was also analyzed immunohistochemically. A Tukey’s honestly significant difference test was
used to evaluate the statistical significance of difference in the macroscopic, histological and immnohistochemical
results.
Results: All treatment groups exhibited slightly higher resistance to the progression of osteoarthritis than the
control group macroscopically 15 weeks after surgery. Histologically, intra-articular injection of Ctp significantly
reduced cartilage degradation 10 weeks after surgery, and Ctp/HA significantly reduced it 5 weeks after surgery in
comparison with the control. Immunohistochemically, both Ctp-treated and Ctp/HA-treated groups had
significantly increased type II collagen-positive chondrocytes at the fifth week after the surgery, although the
numbers of matrix metalloproteinase-13-positive chondrocytes were not affected.
Conclusion: Periodical injections of Ctp and Ctp/HA delayed progression of cartilage degeneration of early
osteoarthritis induced by anterior cruciate ligament transection in rabbits. This effect appears to be exerted by
promotion of type II collagen synthesis predominantly.
Introduction
Osteoarthritis (OA) is characterized by the progressive
loss of articular cartilage that leads to chronic pain and
functional restrictions in affected joints. The most abun-
dant macromolecules of the extracellular matrix of carti-
lage are type II collagen, aggrecan and hyaluronan (HA),
and chondrocytes are the only cellular components.
Under normal physiologic conditions, chondrocytes
maintain an equilibrium between anabolic and catabolic
activities and express various proteolytic enzymes such
as aggrecanases and matrix metalloprotainases (MMPs),
which mediate a very low matrix turnover responsible
for cartilage remodeling. In pathologic conditions such
as OA, however, production of these enzymes increases
considerably, resulting in aberrant cartilage destruction
[1,2]. Recent research for OA treatment has focused on
finding agents aimed at reducing the catabolic factors in
OA, thus slowing or reversing OA progression.
Type II collagen, one of the extracellular matrix com-
ponents of cartilage [3], plays a crucial role in its tensile
property, which allows formation of a fibrillar mesh-
work. This fibril meshwork also binds and traps proteo-
glycans and noncollagenous glycoproteins [4,5]. All
collagens consist of three polypeptide chains, termed a
chains, characterized by repeating glycine-X-Y
sequences. Position × is often occupied by proline or
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lysine and position Y by hydroxyproline or hydroxyly-
sine. Glycine is required at every third position to allow
the close packing of a chains within the triple helix [6].
Availability of a pool of these amino acids may thus
improve production of type II collagen by chondrocytes
and facilitate collagen reorganization, subsequently
decreasing destruction of cartilage in OA.
HA is also one of the principal components of carti-
lage matrix, and intra-articular injection of HA is now
widely used in the treatment of OA. Exogenous HA has
been shown to delay degradation of cartilage by inhibit-
ing glycosaminoglycan release from cartilage tissue and
has anti-inflammatory effects by suppressing expression
of MMPs and IL-1b [7]. MMPs are involved in progres-
sive cartilage destruction in arthritis, and MMP-13 activ-
ity has been implicated as playing a central role in
cartilage degeneration in OA [8]. A previous study
showed that HA inhibits IL-1b-stimulated MMP-13 pro-
duction via CD44 in arthritic chondrocytes [9] and this
effect of HA is also favorable to retain collagen mesh-
work. In addition to the effects on the cartilage, HA also
suppressed MMP-13 expression in subchondral bone
[10]. These effects may delay OA progression and the
long-term effect of HA on OA progression has been
shown in a rabbit model [11].
Collagen tripeptide (Ctp) is a highly purified, nonanti-
genic and low-allergenic tripeptide fraction containing
Gly-Xaa-Yaa sequences [12]. Various small peptides
were recently reported to possess growth factor activities
[13]-Ctp exerted beneficial effects on bone fracture heal-
ing by increasing type I collagen gene expression of
osteoblastic cells [14]. Furthermore, Ctp stimulated
chondrocyte type II collagen gene expression in the pre-
liminary in vitro study. From these findings, we
hypothesized that Ctp administration within the joint
would suppress the loss of cartilage matrix by increasing
expression of type II collagen, subsequently preventing
proteoglycan loss and promoting matrix synthesis. In
addition, we hypothesized that combining Ctp and HA
would bring further protective effects for knee OA pro-
gression. The objectives of this study were to investigate
the protective effect of OA development by intra-articu-
lar injection of Ctp and a mixture of Ctp and HA (Ctp/
HA) using an experimental model in which knee OA
develops as a result of anterior cruciate ligament trans-
ection (ACLT) [15-17] in Japanese white rabbits. This




Ctp was provided by Central Research Institute, Jellice
Corp. (Sendai, Japan), and HA by Seikagaku Corp.
(Tokyo, Japan). Briefly, Ctp was prepared from gelatin
derived from pig skin containing type I and type III col-
lagens using a bacterial collagenase (protease-R; Roche,
Basel, Schweiz) that degrades the peptide bonds of col-
lagen at the amino-terminal end of Gly, as previously
described [12]. The digest was deionized with an ion
exchanger (DAION type SK; Mitsubishi Chemical,
Tokyo, Japan) and then passed through a 0.2 μm filter.
Further purification was performed by eliminating the
endotoxins, using an ACP-0013 module (Asahi Chemi-
cal, Tokyo, Japan) and fractionation of the tripeptide
fraction by reverse-phase HPLC. The tripeptide content
consisting of Gly-Xaa-Yaa sequences was >96% after this
purification [12]. The purity of Ctp is expressed as the
content of tripeptides in the fractions, estimated from
the peak integral of the absorbance at 214 nm by HPLC
with a Superdex Peptide gel filtration column (Pharma-
cia Biotech, Uppsala, Sweden).
Solutions of 3.0 mg/ml Ctp dissolved in saline, of 3.0
mg/ml Ctp/HA in which Ctp was dissolved in HA solu-
tion (Supartz, molecular weight 800 kDa, 10 mg/ml; Sei-
kagaku Corp.) and of HA were used. The dose of Ctp
was chosen based on the local effective concentration of
the previous in vitro preliminary study, in which type II
collagen gene expressions of bovine chondrocytes were
stimulated by supplementation of culture medium with
30 μg/ml Ctp (unpublished data; Y Sakai and colleagues,
Jellice Corp.). We set the concentration at 3 mg/ml,
1,000 times more than the local effective concentration,
because of the possibility of Ctp injected into the knee
articularly being distributed throughout the body.
Experimental animals and anterior cruciate ligament
transection surgery for induction of osteoarthritis
Seventy-two mature female Japanese white rabbits were
utilized in the study. Unilateral ACLT was performed
under anesthesia induced by intravenous injection of 30
mg/kg sodium pentobarbital (Dainippon Sumitomo
Pharma, Osaka, Japan). The anterior cruciate ligament
was exposed through a medial parapatellar incision and
transected at the midsubstance with a sharp blade. Com-
plete transection of the anterior cruciate ligament was
confirmed by a positive anterior drawer sign. The capsule
was sutured to render it watertight, followed by skin clo-
sure. All animals were allowed normal cage activity.
All animal experiments in this study followed the Guide-
lines for Animal Experimentation, Hirosaki University.
Experimental protocol for treatment
After ACLT, the rabbits were divided into four groups
of 18 rabbits each: Group 1 was injected with sterile
physiological normal saline as a control, Group 2 with
Ctp, Group 3 with HA and Group 4 with Ctp/HA.
Using a 27 G needle inserted through the lateral infra-
patellar area toward the intercondylar space of the
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femur in each animal in a deep knee-flexed position, 0.3
ml of each reagent was administrated intra-articularly
into the right knee with ACLT. The first injection was
given immediately after ACLT; each of the six animals
of each group were administered once weekly for 5, 10
and 15 weeks, and all animals were sacrificed by an
overdose of sodium pentobarbital 1 week after the final
injection was administered. The knee joints were then
harvested and evaluated.
Gross morphological examination
Gross morphological changes of the medial condyles of
femur were assessed and graded as previously described
[18] after application of India ink: grade 1 (score 0;
intact surface), surface normal in appearance and does
not retain India ink; grade 2 (score 1; minimal fibrilla-
tion), surface retains India ink as elongated specks or
light-gray patches; grade 3 (score 2; overt fibrillation),
areas that are velvety in appearance and retain ink as
intense black patches; and grade 4 (score 3; erosion),
loss of cartilage exposing the underlying bone. In a
blinded manner, the assessment was conducted by two
independent examiners, who were blinded to each
other’s findings and to the treatment group assignment
of the animals. Finally, the two scores from the exami-
ners were averaged to obtain an overall score.
Histopathological examination
Dissected medial condyles of the femur were fixed in
10% neutral buffered formalin after gross morphological
examination. Specimens were decalcified in 4% ethyle-
mediamine tetraacetic acid solution, dehydrated with a
gradient ethanol series, and embedded in paraffin
blocks. Histological evaluation was performed on sagittal
sections of cartilage removed from each medial condyle
of the femur. Based on macroscopic observation, three
serial sections of 4 μm including the most severely
degenerated area of the weight-bearing lesional areas
were stained with Safranin-O fast green for light micro-
scopic examination. Histological sections were visualized
using an Olympus BX41 microscope (Olympus, Tokyo,
Japan) and Olympus DP2-BSW software (Olympus).
One section was selected that had high quality and was
representative of the three sections. Histological sections
were assessed in a blinded manner by a pathologist who
was unaware of the treatment group assignment of the
animals, and was quantified using the histological grad-
ing system recommended by Osteoarthritis Research
Society International (OARSI) [19].
Immunohistochemical analysis
Cartilage specimens from the medial condyles of the
femur were processed for immunohistochemical analy-
sis. Three serial sections (4 μm) were stained with
mouse mAb against human type II collagen (Daiichi
Fine Chemical, Toyama, Japan) at a dilution of 1:100
and three serial sections (4 μm) were stained with
mouse mAb against rabbit MMP-13 (CHEMICON
International, Inc., Temecula, CA, USA) at a dilution of
1:25 on an automated Benchmark system (Ventana
Medical Systems, Inc., Tucson, AZ, USA). In negative
control sections, the primary antibody was omitted or
irrelevant antibody was applied at the same concentra-
tion as the primary antibody. Image analysis was per-
formed with multiple digital photomicrographs
(Olympus) of sections taken under a high-power field
(×400).
The presence of antigen in the cartilage was estimated
by determining the number of chondrocytes that stained
positive from the superficial zone to the upper two-
thirds of hyaline cartilage. One representative section
from each medial condyle of the femur was examined
and scored. Before evaluation, we ensured that an intact
cartilage surface for each OA specimen could be
detected and used as a marker for validation of the mor-
phometric analysis. The total number of chondrocytes
and those staining positive in each section for the speci-
fic antigen were determined. The counted area was 6.76
× 104 μm2. Results are expressed as the percentage of
chondrocytes staining positive for the antigen, with the
maximum score being 100%. Each section was assessed
in a blinded manner by a pathologist who was unaware
of the treatment group assignment of the animals.
Statistical analysis
All data are expressed as mean ± standard deviation.
Means of groups were compared by analysis of variance
and post-hoc test, with a Tukey’s honestly significant dif-
ference test used to evaluate the statistical significance
of difference in the macroscopic, histological and




There were no adverse effects due to injections in any
rabbit, and no evidence of postoperative infection was
noted. All specimens from the ACLT knees exhibited
complete transection of the anterior cruciate ligament at
sacrifice. All specimens exhibited changes consistent
with the development of knee OA and showed mild to
severe degradation of the condyle cartilage (Figure 1A).
The control and Ctp injection groups exhibited signifi-
cant progression of macroscopic OA score at 10 and 15
weeks compared with 5 weeks after surgery (control: 5
weeks, 1.2 ± 0.4; 10 weeks, 2.5 ± 0.5; 15 weeks, 2.8 ±
0.8; Ctp: 5 weeks, 1.7 ± 0.4; 10 weeks, 2.5 ± 0.5; 15
weeks, 2.2 ± 0.4) (P <0.05; Figure 1B). The score of the
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HA injection group also tended to increase gradually
(HA: 5 weeks, 1.7 ± 0.5; 10 weeks, 2.0 ± 0.6; 15 weeks,
2.2 ± 0.5), and that of the Ctp/HA injection group was
significantly increased at 15 weeks after surgery (Ctp/
HA: 5 weeks, 1.3 ± 0.5; 10 weeks, 2.0 ± 0.0; 15 weeks,
2.3 ± 0.5) (P <0.05). However, there were no statistically
significant differences in the macroscopic scores among
the four groups at 5, 10 and 15 weeks (Figure 1B).
Assessment of effect of Ctp or Ctp/HA on cartilage
preservation
In the knees of the control group, safranin-O staining
was severely reduced at an early stage; and as the num-
ber of injections progressed, the gradual loss of cartilage
matrix was seen (Figure 2A). In some specimens of the
control group, cluster formation was recognized 5, 10
and 15 weeks after injection. Conversely, treated groups
Figure 1 Temporal changes in gross morphology in a rabbit osteoarthritis model. (A) Macroscopic observation of articular cartilage of
medial femoral condyle stained with India ink. (B) Macroscopic score for medial femoral condylar cartilage lesions in each group 5, 10 and 15
weeks after surgery. Ctp, collagen tripeptide; HA, hyaluronan. Data presented as mean ± standard deviation (*P <0.05).
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Figure 2 Inhibitory effects of collagen tripeptide, hyaluronan and collagen tripeptide/hyaluronan on osteoarthritis development. (A)
Histologies of the medial femoral condylar cartilage stained with safranin-O. Arrow indicates cluster formation (original magnification ×100). (B)
Appearance of safranin-O (×100) staining in the medial femoral condylar cartilage from a normal rabbit knee. (C) Osteoarthritis Research Society
International (OARSI) {AU Query: Confirm definition} score for medial femoral condylar cartilage lesions in each group 5, 10 and 15 weeks after
surgery. Ctp, collagen tripeptide; HA, hyaluronan. Data presented as mean ± standard deviation (*P <0.05).
Naraoka et al. Arthritis Research & Therapy 2013, 15:R32
http://arthritis-research.com/content/15/1/R32
Page 5 of 10
had slightly reduced safranin-O staining at five injection
points, and then slowly decreased at 10 and 15 weeks
after surgery (Figure 2A). Cartilage structure was main-
tained until a comparatively late stage. Cluster formation
was also recognized in some specimens of treated
groups. Histological scores for the Ctp/HA group
injected for 5 weeks were significantly decreased in
comparison with the control group (Figure 2B). Ten
weeks after surgery, the Ctp and HA groups exhibited
significantly lower scores than the control group (Figure
2B). Furthermore, the HA group maintained a lower
score than the control group at 15 weeks after surgery.
Weekly Ctp or Ctp/HA injection increases type II collagen
expression during early development of osteoarthritis
The expression of type II collagen was comparable
between the control group and the HA group 5 weeks
after surgery (Figure 3A,C). In both groups, type II col-
lagen was stained in a lower number of chondrocytes.
In contrast, many chondrocytes expressed type II col-
lagen in the Ctp or Ctp/HA groups at the same time
points (Figure 3B,D), and the number of type II col-
lagen-positive chondrocytes in these groups were signifi-
cantly increased in comparison with the control or HA
groups (Figure 3E).
Weekly HA injection decreases MMP-13 expression during
early development of osteoarthritis
MMP-13 expression in chondrocytes of the HA group
significantly decreased in comparison with the control
group, while Ctp or Ctp/HA treatment did not have any
effect on MMP-13 expression 5 weeks after surgery (Fig-
ure 4A,B,C,D,E). Ten weeks after surgery the immunos-
taining results of MMP-13 were not significantly
different among the groups, but tended to decrease in
the Ctp or HA groups 15 weeks after surgery (Figure
4E).
Discussion
Collagen peptides have recently been reported to possess
various biological activities for various cell types [13,20],
and combining HA and amino acids was shown to have
positive effects on the synthetic ability of fibroblasts [21].
In this study, we demonstrated that weekly injection of
Ctp or Ctp/HA delayed the cartilage degeneration in a
very early stage of OA progression or in the initiation of
OA in an ACLT model of Japanese white rabbits.
In the control group injected with saline, significant
loss of safranin-O staining and structural cartilage
damage were noted 5 weeks after surgery, probably due
to the decreased synthesis of type II collagen and aggre-
can by chondrocytes and the subsequent increased pro-
teolytic activity by MMPs and aggrecanases. On the
contrary, a reduction of cartilage damage in the treated
groups was confirmed by the OARSI scoring system.
These effects on cartilage can be explained by two dif-
ferent mechanisms: enhancement of cartilage matrix
synthesis, and inhibition of cartilage degeneration.
Our results showed that the intra-articular injection of
Ctp brought a lower OARSI score 5 weeks after surgery,
and significantly decreased 10 weeks after surgery in
comparison with the control group. Previous studies
showed that Ctp enhanced type I collagen production of
human osteoblastic cells [14] and hyaluronic acid pro-
duction in human dermal fibroblasts [22]. Although the
mechanisms underlying the actions of Ctp for chondro-
cytes are not fully understood, a previous study also
showed that supplementation of culture medium with
tripeptide induced type II collagen synthesis predomi-
nantly by chondrocytes [13]. The results of present
study showed that the number of type II collagen-posi-
tive chondrocytes was significantly increased in the Ctp
treated group 5 weeks after surgery, and there was some
possibility that Ctp enhanced type II collagen produc-
tion of chondrocytes. Furthermore, the deposition of
newly synthesized collagen necessary for cartilage reor-
ganization may be enhanced by availability of tripep-
tides. Intra-articular injection of Ctp is one of the few
attempts to favor the delivery of tripeptides directly to
the site of the lesion, because all collagens consist of
three polypeptide chains, termed a chains, characterized
by repeating glycine-X-Y sequences. Sufficient supply of
tripeptide is enabled to reach the chondrocytes, presum-
ably by diffusion through the cartilage matrix via the
synovial fluid and various transporter systems. Deposi-
tion of newly synthesized type II collagen necessary for
cartilage anabolism may therefore be enhanced by both
availability of tripeptides and activation of chondrocytes’
synthetic ability, subsequently reducing cartilage
degradation.
Regarding the catabolic aspect, many proteases have
been shown to play major roles in the catabolism of OA
cartilage. MMP-13 has been demonstrated to play a pre-
dominant role in the degeneration of type II collagen in
OA cartilage [8]. In the present study, treatment with
Ctp did not affect the number of MMP-13-positive cells;
however, intra-articular injection of HA did significantly
suppress the increase in the number of MMP-13-posi-
tive chondrocytes only 5 weeks after surgery. Previous
in vivo study of the rabbit ACLT model showed that
intra-articular injection of HA did not suppress MMP-
13 mRNA expression in cartilage 10 weeks after surgery
[10], and our results from the 10th and 15th weeks were
consistent with the previous result. However, early inter-
vention of HA treatment suppressed MMP-13 expres-
sion in cartilage in the early phase of our model.
Previous studies have shown that HA inhibits chondro-
cyte MMP-13 activity through CD44 and mitogen-
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activated protein kinase p38 in vitro [12] and that
MMP-13 expression in cartilage of the ACLT model
was relatively higher in the early phase [10]. These
results indicate that HA has chondroprotective effects in
OA initiation. Moreover, our results showed that the
intra-articular injection of HA significantly decreased
the OARSI score 10 and 15 weeks after surgery in com-
parison with the control group. A previous study
showed that intra-articular injection of HA suppressed
MMP-13 mRNA expression in subchondral bone 10
Figure 3 Type II collagen expression during osteoarthritis development. Immunohistochemical findings for type II collagen in the medial
femoral condylar cartilage from (A) a control knee, (B) a collagen tripeptide (Ctp)-treated knee, (C) a hyaluronan (HA)-treated knee and (D) a
Ctp/HA-treated knee 5 weeks after surgery (original magnification ×400). (E) Appearance of type II collagen (×400) staining in the medial femoral
condylar cartilage from a normal rabbit knee. (F) Population of type II collagen-positive chondrocytes in medial femoral condylar cartilage of
each group 5, 10 and 15 weeks after surgery. Counted area was 6.76 × 104 μm2. Data presented as mean ± standard deviation (*P <0.05).
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weeks after surgery [10], and the results of our study
may indicate a suppressive effect of HA on MMP-13
expression in subchondral bone.
Various scaffold material mixtures have been devel-
oped recently for tissue regeneration, exerting a
synergetic effect by different biological activities [21,23].
In the present study, we performed intra-articular injec-
tion of a mixture of Ctp and HA with expectation for
type II collagen synthesis and reduction of type II col-
lagen degradation by chondrocytes. Five weeks after
Figure 4 Matrix metalloproteinase-13 expression during osteoarthritis development. Immunohistochemical findings for matrix
metalloproteinase (MMP)-13 in the medial femoral condylar cartilage from (A) a control knee, (B) a collagen tripeptide (Ctp)-treated knee, (C) a
hyaluronan (HA)-treated knee and (D) a Ctp/HA-treated knee 5 weeks after surgery (original magnification ×400). (E) Appearance of the MMP-13
(×400) staining in the medial femoral condylar cartilage from a normal rabbit knee. (F) Population of MMP-13-positive chondrocytes in medial
femoral condylar cartilage of each group 5, 10 and 15 weeks after surgery. Counted area was 6.76 × 104 μm2. Data presented as mean ±
standard deviation (*P <0.05).
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surgery, the Ctp/HA-treated group showed a significant
increase of type II collagen-positive chondrocytes and a
significant decrease of OARSI score in comparison with
the control group, although the number of MMP-13-
positive chondrocytes was not affected. These results
suggest that the promotion of type II collagen synthesis
by Ctp may contribute predominantly to the prevention
of cartilage destruction. On the contrary, the intra-
articular injection of Ctp/HA did not completely control
MMP-13 production from articular cartilage, despite
our intentions. Perhaps some kind of biological mechan-
ism may have interfered with the Ctp/HA synergetic
effect. Further study is needed to explore whether the
chondroprotective effects of Ctp/HA demonstrated in
the current study relate to the regulation of MMP-13 by
chondrocytes.
Weekly Ctp injection suppressed progression of carti-
lage degeneration 10 weeks after surgery and Ctp/HA
injection 5 weeks after surgery in comparison with the
control group. These effects were decreased 15 weeks
after surgery, however, and Ctp or Ctp/HA treatment
significantly enhanced the number of type II collagen-
positive cells only 5 weeks after surgery. These findings
indicated that chondrocytes changed from anabolic to
catabolic characteristics 10 weeks after surgery and Ctp
and Ctp/HA treatment delayed only the early phase of
OA. Unfortunately, these findings support our hypoth-
esis limitedly in the initiation period of OA. The possi-
ble cause attributed to the results of the present OA
model might be that the mechanical stress loaded to the
articular cartilage was too strong, or that the injected
concentrations of Ctp or Ctp/HA were not sufficient to
neutralize the mechanical stress-induced collagen degen-
eration and cartilage destruction. If the synthesis of car-
tilage matrix could be increased further by adjusting the
injection concentration of Ctp, it might be applied at
the later stages of OA progression. Further examination
is needed to determine the optimal dose, frequency and
duration of Ctp injection therapy for the OA knee,
based on in vitro studies and several additional in vivo
studies.
Conclusion
We demonstrated a novel therapeutic effect of Ctp that
may be applicable to OA. Our results suggested that the
intra-articular injection of Ctp and Ctp/HA seemed to
be effective for the initiation period of cartilage degen-
eration partly by promotion of type II collagen synthesis
and prevention of proteoglycan loss. We advocate that
periodic intra-articular injections of Ctp have potential
as a disease-modifying therapy for patients with the very
early stage of OA progression.
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